Position in ZYME
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$8,654,374
+$2,389,888 QoQ
Shares Held
345,622
+45.3% QoQ
Ownership
0.473%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Hillsdale Investment Management Inc. holds $85,671,146 across 25 Biotechnology names. ZYME ranks #3 (10.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
167,742 | $12,456,520 | |
| 2 | AXSM |
Axsome Therapeutics, Inc.
|
53,363 | $9,019,414 | |
| 3 | ZYME |
Zymeworks Inc.
This page
|
345,622 | $8,654,374 | |
| 4 | HALO |
Halozyme Therapeutics, Inc.
|
110,050 | $7,112,531 | |
| 5 | MIRM |
Mirum Pharmaceuticals, Inc.
|
59,730 | $5,517,857 | |
| 6 | ENTA |
Enanta Pharmaceuticals Inc
|
435,510 | $5,500,491 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
182,320 | $5,416,727 | |
| 8 | IONS |
Ionis Pharmaceuticals Inc
|
70,900 | $5,323,881 |
All Filings in ZYME
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $8,654,374 | 345,622 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $6,264,486 | 237,922 | Shares | Sole | 2026-02-10 | |
| 2025-09-30 | $3,696,487 | 216,422 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $2,573,026 | 205,022 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $2,821,776 | 236,925 | Shares | Sole | 2025-05-09 | |
| 2024-12-31 | $3,367,563 | 230,025 | Shares | Sole | 2025-02-11 | |
| No filing history on record for this holder in this stock. | ||||||